Verrica Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary

Verrica Pharmaceuticals

06/08/2026 22:38

Verrica Pharmaceuticals Inc VRCA.OQ reported a quarterly adjusted loss of 54 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of 2 cents.  The mean expectation of six analysts for the quarter was for a loss of 38 cents per share. Wall Street expected results to range from -47 cents to -33 cents per share.
Revenue fell 53.8% to $5.86 million from a year ago; analysts expected $5.73 million. 
Verrica Pharmaceuticals Inc's reported EPS for the quarter was a loss of 62 cents​.
The company reported a quarterly loss of $13.15 million.
Verrica Pharmaceuticals Inc shares had fallen by 10.0% this quarter and lost 33.7% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 4.1% in the last three months.​ 
In the last 30 days, one analyst negatively revised an earnings estimate
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy" 
Wall Street's median 12-month price target for Verrica Pharmaceuticals Inc is $17.00, about 67.6% above its last closing price of $5.51
This summary was machine generated from LSEG data August 6 at 09:38 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.38
-0.54
Missed
Mar. 31 2026 
-0.36
-0.41
Missed
Dec. 31 2025 
-0.79
-0.46
Beat
Sep. 30 2025 
-0.67
-0.03
Beat